The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere ... I would rather take an injectable weight-loss drug, rather than make a diet change.” More than half (62%) disagreed, with ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

For years, drug developers working to treat an advanced form of fatty liver disease known as MASH were chasing wide-open terrain. There were no products on the market, millions of ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

These two drugs contributed to Novo's sales, but as can be seen in the above chart they ... dosing and presents another risk to the long-term sustainability of Novo's GLP-1 sales.

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...